MedPath

HUIHAN WANG

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:0

Trial Phases

2 Phases

Phase 3:1
Not Applicable:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Not Applicable
2 (66.7%)
Phase 3
1 (33.3%)

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial

Phase 3
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2022-05-19
Last Posted Date
2022-05-19
Lead Sponsor
Huihan Wang
Target Recruit Count
130
Registration Number
NCT05382390
Locations
🇨🇳

ShengJing Hospital of China Medical University, Shenyang, Liaoning, China

Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2022-02-28
Last Posted Date
2022-02-28
Lead Sponsor
Huihan Wang
Target Recruit Count
130
Registration Number
NCT05258799
Locations
🇨🇳

ShengJing Hospital of China Medical University, Shenyang, Liaoning, China

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Not Applicable
Recruiting
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2019-11-19
Last Posted Date
2019-11-19
Lead Sponsor
Huihan Wang
Target Recruit Count
20
Registration Number
NCT04168138
Locations
🇨🇳

ShengJing Hospital of China Medical University, Shenyang, Liaoning, China

News

No news found
© Copyright 2025. All Rights Reserved by MedPath